奥氮平减少精神分裂症患者的迟发性多动障碍症状
WESTPORT, CT (Reuters Health) - The antipsychotic medication olanzapine produces sustained improvement in tardive dyskinesia symptoms in patients with schizophrenia, according to Dr. Bruce J. Kinon.
Dr. Kinon, of Lilly Research Laboratories in Indianapolis, Indiana, and colleagues treated 95 patients--60% with schizophrenia, 27.4% with schizoaffective disorder and 12.6% with schizophreniform disorder--with 5 to 20 mg olanzapine daily for 8 months. Tardive dyskinesia had been evident in the patients for a mean of 4.8 years, and the mean cumulative exposure to antipsychotics was 3.5 years during the 5 years prior to the study.
"We were very impressed with the speed of the reduction in tardive dyskinsia symptoms," Dr. Kinon said during an audio conference held Wednesday at the American Psychiatric Association's 53rd Annual Institute on Psychiatric Services in Orlando. Study data were presented Friday during a poster presentation at the meeting.
Dr. Kinon's group noted a significant improvement in tardive dyskinesia symptoms, as determined by Abnormal Involuntary Movement Scale total scores, as early as 1 week into treatment. By the end of 32 weeks of treatment, approximately 70% of patients were no longer classified as having tardive dyskinesia.
The treatment protocol included two distinct 2-week periods in which the olanzapine dosage was reduced at least 75%, to allow for the possibility of tardive dyskinesia rebound that is seen with other antipsychotic treatments. "Tardive dyskinesia rebound did not occur," Dr. Kinon told Reuters Health. This suggests, according to the research group, that the drug has a true ameliorative effect instead of simply masking symptoms.
Approximately 60% of the patients completed the study, Dr. Kinon said. Of the 40 patients who dropped out because of lack of efficacy or adverse events, he noted, none discontinued treatment due to worsening of tardive dyskinesia symptoms.
Olanzapine treatment also improved the psychopathology of schizophrenic patients, the investigators report. Compared with baseline, they noted a significant decrease in Positive And Negative Symptoms Scale total scores at all time points of treatment., 百拇医药
Dr. Kinon, of Lilly Research Laboratories in Indianapolis, Indiana, and colleagues treated 95 patients--60% with schizophrenia, 27.4% with schizoaffective disorder and 12.6% with schizophreniform disorder--with 5 to 20 mg olanzapine daily for 8 months. Tardive dyskinesia had been evident in the patients for a mean of 4.8 years, and the mean cumulative exposure to antipsychotics was 3.5 years during the 5 years prior to the study.
"We were very impressed with the speed of the reduction in tardive dyskinsia symptoms," Dr. Kinon said during an audio conference held Wednesday at the American Psychiatric Association's 53rd Annual Institute on Psychiatric Services in Orlando. Study data were presented Friday during a poster presentation at the meeting.
Dr. Kinon's group noted a significant improvement in tardive dyskinesia symptoms, as determined by Abnormal Involuntary Movement Scale total scores, as early as 1 week into treatment. By the end of 32 weeks of treatment, approximately 70% of patients were no longer classified as having tardive dyskinesia.
The treatment protocol included two distinct 2-week periods in which the olanzapine dosage was reduced at least 75%, to allow for the possibility of tardive dyskinesia rebound that is seen with other antipsychotic treatments. "Tardive dyskinesia rebound did not occur," Dr. Kinon told Reuters Health. This suggests, according to the research group, that the drug has a true ameliorative effect instead of simply masking symptoms.
Approximately 60% of the patients completed the study, Dr. Kinon said. Of the 40 patients who dropped out because of lack of efficacy or adverse events, he noted, none discontinued treatment due to worsening of tardive dyskinesia symptoms.
Olanzapine treatment also improved the psychopathology of schizophrenic patients, the investigators report. Compared with baseline, they noted a significant decrease in Positive And Negative Symptoms Scale total scores at all time points of treatment., 百拇医药